PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor.
PARP抑制剂与阿比特龙联合治疗可克服转移性去势抵抗性前列腺癌的耐药性，且该耐药性与雄激素受体无关。
期刊:Cancers
影响因子:4.4
doi:10.3390/cancers18040560
Mallah Hamza, Soultani Sina, Diabasana Zania, Lindner Véronique, Barthélémy Philippe, Idoux-Gillet Ysia, Massfelder Thierry
